These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 30144784)
1. Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Shah S; Brock EJ; Jackson RM; Ji K; Boerner JL; Sloane BF; Mattingly RR Neoplasia; 2018 Sep; 20(9):951-963. PubMed ID: 30144784 [TBL] [Abstract][Full Text] [Related]
2. Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma. Brock EJ; Jackson RM; Boerner JL; Li Q; Tennis MA; Sloane BF; Mattingly RR PLoS One; 2021; 16(5):e0252314. PubMed ID: 34048471 [TBL] [Abstract][Full Text] [Related]
3. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318 [TBL] [Abstract][Full Text] [Related]
4. Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma Lo PK; Zhang Y; Yao Y; Wolfson B; Yu J; Han SY; Duru N; Zhou Q J Biol Chem; 2017 Jul; 292(27):11466-11484. PubMed ID: 28512126 [TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression. Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308 [TBL] [Abstract][Full Text] [Related]
6. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a. Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225 [TBL] [Abstract][Full Text] [Related]
7. Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS). Geradts J; Groth J; Wu Y; Jin G Breast Cancer Res Treat; 2016 Jun; 157(3):447-59. PubMed ID: 27250000 [TBL] [Abstract][Full Text] [Related]
8. The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma. Moragas N; Fernandez-Nogueira P; Recalde-Percaz L; Inman JL; López-Plana A; Bergholtz H; Noguera-Castells A; Del Burgo PJ; Chen X; Sorlie T; Gascón P; Bragado P; Bissell M; Carbó N; Fuster G Breast Cancer Res; 2024 Aug; 26(1):122. PubMed ID: 39138514 [TBL] [Abstract][Full Text] [Related]
9. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo. Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125 [TBL] [Abstract][Full Text] [Related]
10. Everolimus Inhibits the Progression of Ductal Carcinoma Chen G; Ding XF; Pressley K; Bouamar H; Wang B; Zheng G; Broome LE; Nazarullah A; Brenner AJ; Kaklamani V; Jatoi I; Sun LZ Clin Cancer Res; 2020 Mar; 26(6):1486-1496. PubMed ID: 31871301 [TBL] [Abstract][Full Text] [Related]
11. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells. Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373 [TBL] [Abstract][Full Text] [Related]
12. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Park K; Han S; Kim HJ; Kim J; Shin E Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686 [TBL] [Abstract][Full Text] [Related]
13. Nek2A contributes to tumorigenic growth and possibly functions as potential therapeutic target for human breast cancer. Wang S; Li W; Liu N; Zhang F; Liu H; Liu F; Liu J; Zhang T; Niu Y J Cell Biochem; 2012 Jun; 113(6):1904-14. PubMed ID: 22234886 [TBL] [Abstract][Full Text] [Related]
14. Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function. Sarper M; Allen MD; Gomm J; Haywood L; Decock J; Thirkettle S; Ustaoglu A; Sarker SJ; Marshall J; Edwards DR; Jones JL Breast Cancer Res; 2017 Mar; 19(1):33. PubMed ID: 28330493 [TBL] [Abstract][Full Text] [Related]
15. TBX3 promotes progression of pre-invasive breast cancer cells by inducing EMT and directly up-regulating SLUG. Krstic M; Kolendowski B; Cecchini MJ; Postenka CO; Hassan HM; Andrews J; MacMillan CD; Williams KC; Leong HS; Brackstone M; Torchia J; Chambers AF; Tuck AB J Pathol; 2019 Jun; 248(2):191-203. PubMed ID: 30697731 [TBL] [Abstract][Full Text] [Related]
16. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast]. Yang M; Xu SP; Ao QL Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534 [TBL] [Abstract][Full Text] [Related]
17. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267 [TBL] [Abstract][Full Text] [Related]
18. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions. Mardekian SK; Bombonati A; Palazzo JP Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418 [TBL] [Abstract][Full Text] [Related]
19. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Knudsen ES; Ertel A; Davicioni E; Kline J; Schwartz GF; Witkiewicz AK Breast Cancer Res Treat; 2012 Jun; 133(3):1009-24. PubMed ID: 22134623 [TBL] [Abstract][Full Text] [Related]
20. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]